Literature DB >> 17942383

Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients.

Ki Hyun Baek1, Hae Myung Jeon, Seong Su Lee, Dong Jun Lim, Ki Won Oh, Won Young Lee, Eun Jung Rhee, Je Ho Han, Bong Yun Cha, Kwang Woo Lee, Ho Young Son, Sung Koo Kang, Moo Il Kang.   

Abstract

Changes in bone and mineral metabolism that occur after gastrectomy have long been recognized. Gastrectomy has been identified as a risk factor for decreased bone mass and the increased fracture incidence. Previous investigations concerning postgastrectomy bone disease have been observational studies. No prospective studies have been reported that quantify the amount of bone loss after gastrectomy within the same patients. This study investigated 46 patients undergoing gastrectomy for gastric adenocarcinoma and analyzed 36 patients (58.1+/-10.8 years, 24 men and 12 women) who had dual energy X-ray absorptiometry (DXA) performed before and 1 year after gastrectomy. Systemic adjuvant chemotherapy was administered to 14 patients. Blood was sampled from all patients to determine serum calcium, phosphorous, and bone turnover marker levels before gastrectomy and at 1, 3, 6 and 12 months after surgery and for serum parathyroid hormone (PTH) and 25-hydroxyvitamin D levels before and 12 months after surgery. The mean bone loss in the lumbar spine, total hip, femoral neck, and trochanter, which was calculated as the percentage change from the baseline to the level measured at 12 months, was 5.7% (P<0.01), 5.4% (P<0.01), 6.6% (P<0.01) and 8.7% (P<0.01), respectively. Bone loss was generally greater in the group receiving chemotherapy. The serum calcium and phosphorous levels were not changed significantly and remained within the normal range throughout the observation period. After gastrectomy, the level of ICTP increased and reached a peak at 1 and 3 months, and progressively declined to baseline by 12 months. The osteocalcin levels were not coupled to an increase before 6 months. The level of 25-hydroxyvitamin D at 12 months postgastrectomy was not significantly changed compared to the baseline, however, the PTH levels increased by a mean of 63.6% at 12 months compared to the baseline (P<0.01). Significant correlations were found between the percent change in the BMD at the lumbar spine and total hip and the percentage change for the PTH level from their baselines to 12 months. The changes in the BMD at total hip, femoral neck, and trochanter also correlated to the change in body weight at 12 months. The data obtained by this study provides evidence that profound bone loss occurs in the setting of a bone remodeling imbalance during the early postgastrectomy period and allows the speculation that the gastrectomy related bone loss may be partially due to an overproduction of PTH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942383     DOI: 10.1016/j.bone.2007.08.027

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  15 in total

1.  Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy.

Authors:  M Krause; J Keller; B Beil; I van Driel; J Zustin; F Barvencik; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2014-11-13       Impact factor: 4.507

2.  Prevalence, pathophysiology, screening and management of osteoporosis in gastric cancer patients.

Authors:  Jung Sub Lim; Jong-Inn Lee
Journal:  J Gastric Cancer       Date:  2011-03-31       Impact factor: 3.720

3.  Effects of total gastrectomy on plasma silicon and amino acid concentrations in men.

Authors:  Marcin R Tatara; Witold Krupski; Maria Szpetnar; Andrzej Dąbrowski; Paweł Bury; Anna Szabelska; Anna Charuta; Anna Boguszewska-Czubara; Ryszard Maciejewski; Grzegorz Wallner
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-02

4.  The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis.

Authors:  H J Oh; B-H Yoon; Y-C Ha; D-C Suh; S-M Lee; K-H Koo; Y-K Lee
Journal:  Osteoporos Int       Date:  2019-11-27       Impact factor: 4.507

5.  Risk of osteoporosis after gastrectomy in long-term gastric cancer survivors.

Authors:  Seung Hyun Yoo; Jung Ah Lee; Seo Young Kang; Young Sik Kim; Sung Sunwoo; Beom Soo Kim; Jeong-Hwan Yook
Journal:  Gastric Cancer       Date:  2017-11-21       Impact factor: 7.370

6.  Dietary 2-oxoglutarate mitigates gastrectomy-evoked structural changes in cartilage of female rats.

Authors:  Piotr Dobrowolski; Ewa Tomaszewska; Paulina Kurlak; Stefan G Pierzynowski
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-22

7.  International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study.

Authors:  Geoffrey Roberts; Patrick R Benusiglio; Tanya Bisseling; Daniel Coit; Jeremy L Davis; Sam Grimes; Theresa A Guise; Richard Hardwick; Kirsty Harris; Paul Furman Mansfield; Jeremy Rossaak; Karen Chelcun Schreiber; Peter P Stanich; Vivian E Strong; Pardeep Kaurah
Journal:  Gastric Cancer       Date:  2022-07-13       Impact factor: 7.701

Review 8.  Vitamin D-The Nutritional Status of Post-Gastrectomy Gastric Cancer Patients-Systematic Review.

Authors:  Tomasz Muszyński; Karina Polak; Aleksandra Frątczak; Bartosz Miziołek; Beata Bergler-Czop; Antoni Szczepanik
Journal:  Nutrients       Date:  2022-06-29       Impact factor: 6.706

9.  Bone health in long-term gastric cancer survivors: A prospective study of high-dose vitamin D supplementation using an easy administration scheme.

Authors:  Marta Climent; Manuel Pera; Isabel Aymar; José M Ramón; Luis Grande; Xavier Nogués
Journal:  J Bone Miner Metab       Date:  2017-08-01       Impact factor: 2.626

10.  Negative Effects of Total Gastrectomy on Bone Tissue Metabolism and Volumetric Bone Mineral Density (vBMD) of Lumbar Spine in 1-Year Study in Men.

Authors:  Witold Krupski; Marcin R Tatara; Pawel Bury; Anna Szabelska; Anna Charuta; Ryszard Maciejewski; Grzegorz Wallner; Andrzej Dabrowski
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.